Fig. 2: Reported prevalence of indications in the United States versus prevalence in Roche/Genentech ophthalmology clinical trials. | Eye Open

Fig. 2: Reported prevalence of indications in the United States versus prevalence in Roche/Genentech ophthalmology clinical trials.

From: Racial and ethnic diversity in ophthalmology: a meta-analysis of industry-sponsored phase 3 clinical trials from a single company

Fig. 2: Reported prevalence of indications in the United States versus prevalence in Roche/Genentech ophthalmology clinical trials.

For nAMD/GA prevalence rates were obtained from the CDC VEHSS report based on estimates from 2019 [14]. For RVO, prevalence rates were obtained from CDC VEHSS using 2019 estimates for “other eye disorders,” “other retinal disorders,” “diagnosed by type,” “diagnosed BRVO or CRVO” [15]. For DR/DMO, prevalence rates were obtained from the CDC VEHSS report based on estimates from 2021 [16]. BRVO branched retinal vascular occlusion, CDC Centers for Disease Control and Prevention, CRVO central retinal vascular occlusion, DMO diabetic macular oedema, DR diabetic retinopathy, GA geographic atrophy, nAMD neovascular age-related macular degeneration, RVO retinal vascular occlusion, VEHSS Vision and Eye Health Surveillance System.

Back to article page